PAYBACK: TRACKING THE OPIOID SETTLEMENT CASH
Hace 18 horas
miércoles, 31 de enero de 2024
martes, 30 de enero de 2024
Why Be a Fellow @ DCEG: Launching Your Future
Career Paths of our Alumni: Q&A with Former Fellows
https://dceg.cancer.gov/fellowship-training/fellowship-experience/former-fellows-qa
Fellowships & Training
https://dceg.cancer.gov/fellowship-training
Why SBIR?
NCI's Small Business Innovation Research (SBIR) program is committed to bring innovative cancer technology to patients. Watch to learn the important role the program plays in bringing innovations to life to help people live healthier lives.
Fellows Talk about DCEG
https://dceg.cancer.gov/fellowship-training/fellowship-experience/fellows-talk-about-dceg?cid=eb_govdel
How to Apply for DCEG Fellowships
https://dceg.cancer.gov/fellowship-training/apply?cid=eb_govdel
Research in Context: Diagnosing dementia
Research in Context: Diagnosing dementia
https://www.nih.gov/news-events/nih-research-matters/research-context-diagnosing-dementia
lunes, 29 de enero de 2024
TAX TALK: STRATEGIES FOR FILING IN 2024
Tax Talk: Strategies for Filing In 2024
By Ivanhoe Broadcast News on February 4, 2024
https://www.ivanhoe.com/?p=32394&preview=1&_ppp=2c18f08757
SAD DOGS: SEASONAL DEPRESSION HAS FIDO FEELING DOWN
SAD Dogs: Seasonal Depression Has Fido Feeling Down
By Ivanhoe Broadcast News on February 3, 2024
https://www.ivanhoe.com/?p=32392&preview=1&_ppp=31ce278de0
WHAT REALLY MAKES KIDS FEEL LOVED?
What Really Makes Kids Feel Loved?
By Ivanhoe Broadcast News on February 3, 2024
https://www.ivanhoe.com/?p=32390&preview=1&_ppp=df52058689
TECH DETOX: HOW TO DISCONNECT
Tech Detox: How to Disconnect
By Ivanhoe Broadcast News on February 2, 2024
https://www.ivanhoe.com/?p=32388&preview=1&_ppp=44965e0452
EMPOWERED LEGACIES: TRAILBLAZING BLACK WOMEN WHO SHAPED HISTORY
Black Women Who Shaped History
By Ivanhoe Broadcast News on February 1, 2024
https://www.ivanhoe.com/?p=32386&preview=1&_ppp=d178a5b29a
BLUE LIGHT MAKES BLADDER CANCER GLOW PINK
Blue Light Makes Bladder Cancer Glow Pink
By Ivanhoe Broadcast News on January 31, 2024
https://www.ivanhoe.com/?p=32373&preview=1&_ppp=ff7ee5d49b
DETECTING NEC QUICKLY SAVES PREEMIES
Detecting NEC Quickly Saves Preemies
By Ivanhoe Broadcast News on January 30, 2024
https://www.ivanhoe.com/?p=32366&preview=1&_ppp=693f36588a
BIONIC PANCREAS: TYPE 1 DIABETES CAN’T STOP THIS GYMNAST
Type 1 Diabetes Can’t Stop This Gymnast
By Ivanhoe Broadcast News on January 29, 2024
https://www.ivanhoe.com/medical-breakthroughs/type-1-diabetes-cant-stop-this-gymnast/
domingo, 28 de enero de 2024
Challenges and opportunities in spinal muscular atrophy therapeutics. Crystal J J Yeo et al. Lancet Neurol 2024 1 (2) 205-218 (Posted Jan 26, 2024 10AM)
https://phgkb.cdc.gov/PHGKB/specificPHGKB.action?topic=nd&query=home
From the abstract: " Spinal muscular atrophy was the most common inherited cause of infant death until 2016, when three therapies became available: the antisense oligonucleotide nusinersen, gene replacement therapy with onasemnogene abeparvovec, and the small-molecule splicing modifier risdiplam. These drugs compensate for deficient survival motor neuron protein and have improved lifespan and quality of life in infants and children with spinal muscular atrophy. Given the lifelong implications of these innovative therapies, ways to detect and manage treatment-modified disease characteristics are needed. All three drugs are more effective when given before development of symptoms."
Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry. Kyung Min Lee et al. J Natl Cancer Inst 2024 1
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=archive&date=01/20/2024
From the abstract: "This cross-sectional retrospective analysis examines the association between a polygenic hazard score (PHS290) and risk of prostate cancer diagnosis upon first biopsy in male Veterans using two-sided tests. Our analysis included 36,717 Veterans (10,297 of African ancestry). Unadjusted rates of positive first prostate biopsy increased with higher genetic risk (low risk: 34%, high risk: 58%; p?
Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis A Ahmad et al, Com Med January 22, 2024
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=archive&date=01/22/2024
From the abstract: " We conducted a systematic review and meta-analysis of longitudinal studies to identify potentially novel prognostic factors that may improve CVD risk prediction in T2D. Out of 9380 studies identified, 416 studies met inclusion criteria. Outcomes were reported for 321 biomarker studies, 48 genetic marker studies, and 47 risk score/model studies."
Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. Wade T Iams et al. JAMA Netw Open 2024 1 (1) e2351700
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=archive&date=01/23/2024
In this cohort study of 3209 patients undergoing concurrent testing across 4 cancer types who received both tissue-based and ctDNA genomic profiling results, 45.1% had a guideline-based variant detected. Of these patients, 9.3% had a clinically actionable variant detected by ctDNA profiling that was not detected by solid-tissue testing, and 24.2% had a variant detected by solid-tissue testing but not by ctDNA profiling; for patients with breast cancer with actionable variants, 20.2% had a unique, guideline-based variant detected by ctDNA profiling; most (55.0%) of these unique ctDNA variants were in the ESR1 gene. The study suggests that concurrent ctDNA–based and tissue-based genomic profiling identified more patients with targetable, guideline-based variants than would have been discovered by tissue profiling alone, with a higher detection rate among patients with breast cancer. "
Assessment of Mendelian and risk factor genes in Alzheimer disease: a prospective nationwide clinical utility study and recommendations for genetic screening G Nicolas et al, Genetics in Med, January 24, 2024
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=archive&date=01/25/2024
From the abstract: "We included 700 patients in a prospective study and performed exome sequencing. A panel of 28 Mendelian and 6 risk-factor genes was interpreted and returned to patients. We built a framework for risk variant interpretation and risk gradation and assessed the detection rates among early-onset AD (EOAD, age of onset (AOO) =65 years, n=608) depending on AOO and pedigree structure and late-onset AD (LOAD, 66
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis Z Raglov et al, Lancet Microbe, January 26, 2024
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=all%20hot%20topics
From the abstract: "In this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance. "
Population Screening for Hereditary Hemochromatosis More than a Quarter Century After Gene Discovery – Current Status and the Path Forward February 15, 2024, 1:00 pm – 2:00 pm ET
https://www.cdc.gov/genomics/events/pop_screen_hereditary_hemochromatosis_2024.htm
Current data suggest that 1 in 300 non-Hispanic White individuals in the United States carry a genetic variation in the HFE gene (C282Y homozygosity) that accounts for most cases of hereditary hemochromatosis (HH). This variation can lead to iron overload and life-threatening complications, such as severe liver disease. However, complications are preventable with early diagnosis and periodic phlebotomies to remove excess iron from the body. At present, Tier 1 evidence-based guidelines support family-based genetic testing for HH. However, uncertainty remains concerning the best strategy for pre-symptomatic case identification and the suitability of HFE-associated HH as a target for population screening or ancestry-targeted screening using either measures of iron status or direct genetic testing. To devise optimal preventive strategies for HH, we must consider existing evidence about HH genetics, penetrance, and prevalence and the acceptability, cost, and effectiveness of potential screening strategies. In this webinar, our speakers will discuss how knowledge about HH has evolved since the discovery of the HFE gene in 1997, current opportunities for clinical and public health action to prevent disease, and future research priorities to advance case detection and reduce clinical complications from HH.
sábado, 27 de enero de 2024
viernes, 26 de enero de 2024
jueves, 25 de enero de 2024
Colorectal cancer is now leading cause of death among young adults with cancer: new report ‘Interplay of risk factors’ likely drives the increase, says colorectal cancer doctor Melissa Rudy By Melissa Rudy Fox News Published January 17, 2024 5:28pm EST | Updated January 17, 2024 5:29pm EST
Colorectal cancer is now leading cause of death among young adults with cancer: new report
‘Interplay of risk factors’ likely drives the increase, says colorectal cancer doctor
Melissa Rudy By Melissa Rudy Fox News
Published January 17, 2024 5:28pm EST | Updated January 17, 2024 5:29pm EST
https://www.foxnews.com/health/colorectal-cancer-leading-cause-death-among-young-adults-cancer-report
Marine vet touts benefits of psychedelic-assisted PTSD drugs as FDA considers MDMA approval Some experts and the VA support MDMA, also known as ecstasy, for mental health treatment — but others urge caution Angelica Stabile By Angelica Stabile Fox News Published January 19, 2024 5:00am EST
Marine vet touts benefits of psychedelic-assisted PTSD drugs as FDA considers MDMA approval
Some experts and the VA support MDMA, also known as ecstasy, for mental health treatment — but others urge caution
Angelica Stabile By Angelica Stabile Fox News
Published January 19, 2024 5:00am EST
https://www.foxnews.com/health/marine-vet-touts-benefits-psychedelic-assisted-ptsd-drugs-as-fda-considers-mdma-approval
11 winter car essentials you can find on Amazon that may save your life Preparing your car for an emergency could make a huge difference if you get stuck in a winter storm Nora Colomer By Nora Colomer Fox News
11 winter car essentials you can find on Amazon that may save your life
Preparing your car for an emergency could make a huge difference if you get stuck in a winter storm
Nora Colomer By Nora Colomer Fox News
https://www.foxnews.com/lifestyle/amazon-winter-car-essentials
What Do Fats Do in the Body? BY RACHEL CROWLEY
https://biobeat.nigms.nih.gov/2024/01/what-do-fats-do-in-the-body/?utm_medium=email&utm_source=govdelivery
Science Snippet: Lipids in the Limelight
BY ABBEY BIGLER-COYNE
https://biobeat.nigms.nih.gov/2022/07/science-snippet-lipids-in-the-limelight/?utm_medium=email&utm_source=govdelivery
HIV and Transgender People: HIV Prevalence
https://www.cdc.gov/hiv/group/gender/transgender/hiv-prevalence.html?utm_campaign=morning_rounds&utm_medium=email&_hsmi=291354684&_hsenc=p2ANqtz-9dTpDepQg0oT5OUNOBDFnSorF72DTyua55c8mfXa4fBc66bluj0bj6wiSVl-0QLnY8ADYjC5QEyBwynMm3IB4qMmN2Hg&utm_content=291354684&utm_source=hs_email
CDC report explores why trans women have higher rates of HIV
Transgender women have a disproportionately high rates of HIV. While those data are solid, the “why” hasn’t been systematically studied. For the first time, the CDC has collected behavioral data relevant to HIV prevention and risk. Its analysis suggests the social and economic marginalization — including violence, homelessness, and incarceration — that trans women experience could explain higher risk for HIV. The survey of more than 1,600 transgender women conducted at sites (where they were offered HIV testing) in seven U.S. cities in 2019 and 2020 found:
42% tested positive for HIV: 62% of Black trans women, 35% of Hispanic and Latina trans women, and 17% of white trans women.
About 10% had been fired for being transgender and 32% had trouble getting a job for that reason, limiting health insurance options.
60% experienced gender-based violence: verbal abuse (53%), physical abuse (26%), or sexual violence (15%) over the last year; almost 18% experienced suicidal ideation.
STAT’s Theresa Gaffney and Annalisa Merelli have more.
Transgender women’s higher risk for HIV is influenced by discrimination, CDC finds
Theresa Gaffney
Annalisa Merelli
By Theresa Gaffney and Annalisa Merelli Jan. 25, 2024
https://www.statnews.com/2024/01/25/transgender-women-hiv-socioeconomic-risks-cdc/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=291354684&_hsenc=p2ANqtz-_ew-gr2PD9LoOQK7Yn_e1LmRYkPZMPJa6UcRLWqnSUXt6D_vmXwGof4yEJdWiFzgOiTX2z8Xy7CxLVDNfxsFpFT4jfqQ&utm_content=291354684&utm_source=hs_email
Need a 'winter reset'? Experts share benefits of slowing down during colder months The concept of 'wintering' has gone viral on TikTok, encouraging people to rest and reflect Angelica Stabile By Angelica Stabile Fox News Published January 23, 2024 6:31am EST
Need a 'winter reset'? Experts share benefits of slowing down during colder months
The concept of 'wintering' has gone viral on TikTok, encouraging people to rest and reflect
Angelica Stabile By Angelica Stabile Fox News
Published January 23, 2024 6:31am EST
https://www.foxnews.com/health/need-winter-reset-experts-share-benefits-slowing-down-colder-months
Ozempic and Wegovy overdose calls have spiked, experts say — here’s what to know about dangerous doses Experts and doctors shared symptoms of taking too much weight-loss medication while manufacturer also weighed in Melissa Rudy By Melissa Rudy Fox News Published January 21, 2024 4:30am EST
Ozempic and Wegovy overdose calls have spiked, experts say — here’s what to know about dangerous doses
Experts and doctors shared symptoms of taking too much weight-loss medication while manufacturer also weighed in
Melissa Rudy By Melissa Rudy Fox News
Published January 21, 2024 4:30am EST
https://www.foxnews.com/health/ozempic-wegovy-overdose-calls-spiked-experts-say-heres-know-dangerous-doses
Prostate cancer myths and common misconceptions from an oncologist amid high-profile cases King Charles II, the King Foundation, Ryan Sandberg and Lloyd Austin have all made prostate cancer announcements recently Melissa Rudy By Melissa Rudy Fox News Published January 22, 2024 6:29pm EST
Prostate cancer myths and common misconceptions from an oncologist amid high-profile cases
King Charles II, the King Foundation, Ryan Sandberg and Lloyd Austin have all made prostate cancer announcements recently
Melissa Rudy By Melissa Rudy Fox News
Published January 22, 2024 6:29pm EST
https://www.foxnews.com/health/prostate-cancer-myths-common-misconceptions-oncologist-amid-high-profile-cases
Alzheimer’s patients divided into 5 subgroups, potentially enabling ‘personalized medicine,’ study finds Finding could explain why some patients don’t respond as well in clinical trials, say researchers Melissa Rudy By Melissa Rudy Fox News Published January 20, 2024 4:30am EST
Alzheimer’s patients divided into 5 subgroups, potentially enabling ‘personalized medicine,’ study finds
Finding could explain why some patients don’t respond as well in clinical trials, say researchers
Melissa Rudy By Melissa Rudy Fox News
Published January 20, 2024 4:30am EST
https://www.foxnews.com/health/alzheimers-patients-divided-subgroups-potentially-enabling-personalized-medicine-study
Ohio mother hopes for a cure to save her son, 8, from rare, fatal disease: ‘Gut-wrenching’ Batten disease causes vision loss, dementia and impaired mobility, with average life expectancy between 8 and 10 Melissa Rudy By Melissa Rudy Fox News Published January 24, 2024 5:50am EST
Ohio mother hopes for a cure to save her son, 8, from rare, fatal disease: ‘Gut-wrenching’
Batten disease causes vision loss, dementia and impaired mobility, with average life expectancy between 8 and 10
Melissa Rudy By Melissa Rudy Fox News
Published January 24, 2024 5:50am EST
https://www.foxnews.com/health/ohio-mother-hopes-cure-save-son-rare-fatal-disease-gut-wrenching
miércoles, 24 de enero de 2024
SARS-CoV-2 can cause lasting damage to cells’ energy production ++
https://www.nih.gov/news-events/nih-research-matters/sars-cov-2-can-cause-lasting-damage-cells-energy-production
How SARS-CoV-2 contributes to heart attacks and strokes
https://www.nih.gov/news-events/nih-research-matters/how-sars-cov-2-contributes-heart-attacks-strokes
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission
https://www.thelancet.com/commissions/global-burden-stroke?dgcid=hubspot_email_conferencealerts_sccm24&utm_campaign=conferencealerts&utm_medium=email&_hsmi=290943338&_hsenc=p2ANqtz--YzxJubE0BB1wLFZhnUWaJO0Isjh4XpyXC7asr_OWdgZ8-MjYFWal0wQk06wvPDl7JonYPq66eUPFekEeF8QJvDzSLrA&utm_content=290943338&utm_source=hs_email
The burden of mortality and disability caused by stroke is rapidly increasing worldwide, particularly in countries where the resources to tackle this burden are scarce. However, the implementation of evidence-based interventions could reverse these epidemiological trajectories. A large proportion of strokes can be prevented and, for most patients who present to a stroke unit during the first few hours after the onset of symptoms, treatment can improve survival and functional outcomes. Furthermore, rehabilitation interventions can reduce disability in stroke survivors, improving quality of life for patients and carers.
In this Lancet Neurology Commission, the World Stroke Organization (WSO) draws up its roadmap to tackle the burden of stroke by 2030 and beyond, in line with the UN Sustainable Development Goal on health and wellbeing. If implemented by policy makers, in collaboration with stakeholders in every country, the WSO recommendations could lead to substantial improvements in prevention of stroke, acute treatment, and rehabilitation worldwide. The Commission also provides guidance on the epidemiological surveillance necessary to monitor progress.
martes, 23 de enero de 2024
CANINE COVID? NEW MYSTERIOUS RESPIRATORY ILLNESS IN DOGS
Respiratory Illness in Dogs: Canine COVID?
By Ivanhoe Broadcast News on January 27, 2024
https://www.ivanhoe.com/?p=32273&preview=1&_ppp=24a046d52a
TEACH YOURSELF SELF-CONFIDENCE: A DIY GUIDE TO GREATNESS
Teach Yourself Self-Confidence: A DIY Guide to Greatness
By Ivanhoe Broadcast News on January 28, 2024
https://www.ivanhoe.com/?p=32276&preview=1&_ppp=63388c58bb
CLEAN SCREENS: STOP POP-UP ADS FROM POPPING UP
Clean Screens: Stop Pop-Up Ads from Popping Up
By Ivanhoe Broadcast News on January 28, 2024
https://www.ivanhoe.com/?p=32279&preview=1&_ppp=0f57a4f793
NON-SURGICAL BREAKTHROUGH FOR RARE URINARY TRACT CANCER
Non-Surgical Breakthrough for Rare Urinary Tract Cancer
By Ivanhoe Broadcast News on January 22, 2024
https://www.ivanhoe.com/medical-breakthroughs/non-surgical-breakthrough-for-rare-urinary-tract-cancer/
SILENT INTRUSION: ACOUSTIC NEUROMAS & HEARING LOSS
Acoustic Neuromas & Hearing Loss: Silent Intrusion
By Ivanhoe Broadcast News on January 23, 2024
https://www.ivanhoe.com/medical-breakthroughs/acoustic-neuromas-hearing-loss-silent-intrusion/
INTERMITTENT FASTING AND BETTER SLEEP FIGHT ALZHEIMER’S
Intermittent Fasting and Better Sleep Fight Alzheimer’s
By Ivanhoe Broadcast News on January 24, 2024
https://www.ivanhoe.com/?p=32288&preview=1&_ppp=ef0fed310e
ADRENAL ROBOTIC SURGERY IS A GAME CHANGER
Adrenal Robotic Surgery is a Game Changer
By Ivanhoe Broadcast News on January 25, 2024
https://www.ivanhoe.com/?p=32291&preview=1&_ppp=1355a5ab47
SACRAL STIMULATORS CHANGE LIVES
Sacral Stimulators Change Lives
By Ivanhoe Broadcast News on January 26, 2024
https://www.ivanhoe.com/?p=32294&preview=1&_ppp=e4b3db6271
Featured Registries and Matching Services: Volunteers needed for studies to advance dementia research
Featured Registries and Matching Services
Volunteers needed for studies to advance dementia research
Asian Cohort for Alzheimer's Disease (ACAD) — Sign up to join a study to identify risk factors associated with Alzheimer's in people of Asian ancestry.
Asian Cohort for Alzheimer's Disease (ACAD)
Start: March 2021
Enrollment: 5000
https://www.alzheimers.gov/clinical-trials/asian-cohort-alzheimers-disease-acad?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Alzheimer's Prevention Trials (APT) Webstudy — Enroll to track memory and thinking skills and learn about Alzheimer’s trials.
Alzheimer Prevention Trials (APT) Webstudy
Start: December 20, 2017
End: April 30, 2023
https://www.alzheimers.gov/clinical-trials/alzheimer-prevention-trials-apt-webstudy?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Alzheimer's Prevention Registry — Get information and updates about participating in future Alzheimer’s prevention trials.
Alzheimer's Prevention Registry
Start: May 2012
End: January 2030
Enrollment: 500000
https://www.alzheimers.gov/clinical-trials/alzheimers-prevention-registry?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Find Clinical Trials
https://www.alzheimers.gov/clinical-trials?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Get more information about these and other Alzheimer’s clinical trials online. Or call the ADEAR Center at 800-438-4380 or email adear@nia.nih.gov.
Volunteers needed for studies to advance dementia research
Volunteers needed for studies to advance dementia research
Lifestyle and Exercise
MIND Diet and Aerobic Training To Improve Cognition in Black Adults With High Blood Pressure (Indianapolis, IN)
MIND Diet and Aerobic Training To Improve Cognition in Black Adults With High Blood Pressure
Start: Nov. 28, 2023
End: May 31, 2027
https://www.alzheimers.gov/clinical-trials/mind-diet-and-aerobic-training-improve-cognition-black-adults-high-blood-pressure?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE) (Baton Rouge, LA)
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)
Start: Aug. 9, 2019
End: Nov. 30, 2026
https://www.alzheimers.gov/clinical-trials/raate?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Retain Your Brain Health Study for Older Adults With a Family History of Alzheimer's Disease (online)
Retain Your Brain Health Study for Older Adults With a Family History of Alzheimer's Disease
Start: Dec. 7, 2023
End: Sept. 7, 2024
https://www.alzheimers.gov/clinical-trials/retain-your-brain-health-study-older-adults-family-history-alzheimers-disease?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
ACP-204 for Alzheimer's Disease Psychosis Start: Nov. 14, 2023 End: February 2028
New and featured studies
Click on the trial name for details and contact information.
https://www.alzheimers.gov/clinical-trials/acp-204-alzheimers-disease-psychosis?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Sargramostim for Mild to Moderate Alzheimer's Disease
Start: June 1, 2022
End: July 2024
https://www.alzheimers.gov/clinical-trials/sargramostim-mild-moderate-alzheimers-disease?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Negotiation Training To Improve Well-Being in Dementia Caregivers Start: Sept. 1, 2023 End: March 2025
New and featured studies
Click on the trial name for details and contact information.
https://www.alzheimers.gov/clinical-trials/negotiation-training-improve-well-being-dementia-caregivers?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
Phone-based Guided Imagery To Improve Family Dementia Caregiver Well-Being
Start: Nov. 1, 2023
End: June 30, 2024
https://www.alzheimers.gov/clinical-trials/phone-based-guided-imagery-improve-family-dementia-caregiver-well-being?utm_source=nia-eblast&utm_medium=email&utm_campaign=clinicaltrials-20240122
2024 FEB CCSS: Clinical Considerations and Current Trends in Women's Health February 22, 2024
https://www.dhaj7-cepo.com/content/2024-feb-ccss
Greetings,
Registration is OPEN for the upcoming Clinical Communities Speaker Series (CCSS), "Clinical Considerations and Current Trends in Women's Health” occurring on February 22nd, 2024, 7:15 a.m. - 3:15 p.m. (ET). This live event offers up to 6.0 Continuing Education/Continuing Medical Education (CE/CME) credits. Register here: https://www.dhaj7-cepo.com/content/2024-feb-ccss
Purpose
The Defense Health Agency (DHA), J-7 (Education and Training Directorate), Continuing Education Program Office (CEPO) Clinical Communities Speaker Series (CCSS) events are designed to address the professional practice gaps of our learners to improve the care that our health care professionals deliver. This Continuing Education/Continuing Medical Education (CE/CME) event is conducted to achieve results that reflect a change in skills, competence, and performance of the health care team, and patient outcomes. Collaboration occurs with the Department of Defense, several government agencies, and other civilian experts for recruitment of academic subject matter experts, clinicians, and researchers to present on current promising, evidence-based research and best practices, thus enhancing the overall educational experience. Participants are expected to apply what they learned in providing patient care individually and collaboratively as a team towards improved patient outcomes.
Target Audience
Physicians, Nurses, Pharmacists, Pharmacy Technicians, Physician Assistants, Dentists, Dental Hygienists, Dental Technicians, Social Workers, Psychologists, Registered Dieticians, Dietetic Technicians, Occupational Therapists/Occupational Therapy Assistants, Athletic Trainers, Case Managers, Certified Counselors, Physical Therapists/Physical Therapist Assistants, Kinesiotherapists, Healthcare Executives, and other health care professionals who support/ care for U.S. active-duty service members, reservists, Coast Guard, Public Health Service, National Guardsmen, military veterans and their families.
Program Overview
This event will explore the evidence-based practices in women’s health care from the Department of Defense, Defense Health Agency, Walter Reed National Military Medical Center, Johns Hopkins University School of Medicine, Catholic University, Florida Atlantic University, the Veterans Health Administration, and other top community practice groups. The educational content will be created by Subject Matter Experts in the ethics, research, academia, and medical domains of military and civilian health care sectors. The primary focus of this event aims to enhance the quality of patient outcomes and population health by providing advanced continuing education opportunities to improve the practice, skills, and knowledge of health care providers across the Military Health System.
Program Agenda
7:15 - 7:20 a.m. (ET) - Welcome Remarks
Lolita T. O’Donnell, Ph.D., M.S.N., R.N.
Division Chief
Leadership Education Analysis Development Sustainment (LEADS) Division
Academic Superintendent, Continuing Education Program Office (CEPO),
Education and Training (E&T) Directorate, J-7
Defense Health Agency (DHA)
Falls Church, Va.
7:20 – 7:30 a.m. (ET) - Opening Remarks
Army Col Maria Molina, M.D., F.A.C.O.G., F.A.C.S., C.H.S.E.
Acting Director, J-7, Education and Training
Defense Health Agency
Fall Church, Va.
Moderator
Army Lt. Col. Noelle Dove, D.N.P., R.N., C.N.M.
Deputy Director
U.S. Army Obstetrics and Gynecology Nursing Course
Fort Cavazos, Texas
07:30 –08:30 a.m. (ET) - S01: "An Analysis of the Cardiovascular and Hypertensive Disease in Pregnancy: Outcomes and Disparities"
Rita W. Driggers, M.D., F.A.C.O.G.
Associate Professor of Gynecology and Obstetrics
Johns Hopkins University School of Medicine
Medical Director, Maternal Fetal Medicine Sibley
Memorial Hospital Johns Hopkins Medicine
Washington, D.C.
08:40 – 09:40 a.m. (ET) - S02: “Ethical Issues Associated with the Care of Women and Children During Wartime”
Army Lt. Col. (Ret) Janice Agazio, Ph.D., C.R.N.P., R.N., F.A.A.N.P., F.A.A.N.
Associate Dean for Doctoral Program
Ordinary Professor, School of Nursing
The Catholic University of America
Washington, D.C.
Air Force Col. (ret) Candy Wilson, Ph.D., A.P.R.N., W.H.N.P.-B.C., F.A.A.N.P., F.A.A.N.
Interim Associate Dean of Research and Scholarship
Schmidt Family Distinguished Professor
Associate Professor, Christine E Lynn College of Nursing
Florida Atlantic University
Boca Raton, Fla.
09:50 - 10:50 a.m. (ET) - S03: “Implementation Journey of Postpartum Hemorrhage Bundle and Walk-in Contraception Services”
Susanna Didrickson Ph.D., R.N.C.-O.B., W.H.N.P.-B.C.
Nurse Consultant, Women’s Health Clinical Management Team
Directorate of Medical Affairs, Office of Clinical Support
Assistant Director for Healthcare Administration
Defense Health Agency
Falls Church, Va.
11:00 a.m. – 12:00 p.m. (ET) - S04: "Pelvic Health Topic”
Air Force Col. Heather M. Barbier, M.D., M.P.H., F.A.C.O.G., F.A.C.S.
Gynecologic Surgery & Obstetrics (GS&O) Residency, Program Director
Female Pelvic Medicine & Reconstructive Surgery, Physician
Associate Professor of GS&O, Uniformed Services University of the Health Sciences
Walter Reed National Military Medical Center
Bethesda, Md.
Katherine Miles, D.P.T., P.T., W.C.S.
Pelvic Health Physical Therapist
Walter Reed National Military Medical Center
Female Pelvic Medicine & Reconstructive Surgery Fellowship Program
Assistant Professor of Obstetrics & Gynecology at the Uniformed Services University of the Health Sciences
Bethesda, Md.
Danielle Worthington, Ph.D.
Women’s Health Psychologist
Clinical Psychologist
Walter Reed National Military Medical Center
Bethesda, Md.
1:00 – 2:00 p.m. (ET) - S05: "2023 Department of Veterans Affairs /Department of Defense Clinical Practice Guideline on Pregnancy: Updates to Clinical Care and Application”
Carrie Kairys, D.N.P., F.N.P.-B.C.
Deputy Field Director, Area 2
Office of Women’s Health (10W)
Veteran Health Central Office
Durham, N.C.
Michael Clark, M.D., F.A.C.O.G.
Staff Physician, Department of Gynecologic Surgery & Obstetrics
Associate Director, Obstetrics & Gynecology Residency Program
Madigan Army Medical Center
Joint Base Lewis-McChord, Wash.
2:10 – 3:10 p.m. (ET) - S06: "Research, Interventions and Equitable Care Updates in Premenstrual and Perimenopausal Women: A Focus on Improving Mental Health”
Navy Capt. Paulette Cazares, M.D., M.P.H.
Psychiatrist, Navy Medicine Readiness and Training Command
Naval Medical Center San Diego
San Diego, Calif.
Laura J. Miller, M.D.
Medical Director of Reproductive Mental Health
Women’s Mental Health, Office of Mental Health and Suicide Prevention
Veterans Affairs
3:10 – 3:15 p.m. (ET) - Closing Remarks
Air Force Col. Larissa Weir, M.D., F.A.C.O.G.
Chair, DHA Women and Infants Clinical Community
Air Force Surgeon General Chief Women’s Health Consultant Readiness Analysis Comprehensive Evaluation Team
Air Force Medical Readiness Agency
Associate Professor of Gynecologic Surgery and Obstetrics, Uniformed Services University Health Sciences
Falls Church, Va.
This agenda is subject to change.
Please visit the following website to register: https://www.dhaj7-cepo.com/content/2024-feb-ccss
Continuing Education
This CE/CME activity is provided through the DHA J-7 CEPO and is approved for a total of 6.0 CE/CMEs.
Commercial Support
No commercial support was provided for this activity.
Participation Costs
There is no cost to participate in this activity.
CE/CME Inquiries
For all CE/CME related inquiries, please contact us at: dha.ncr.j7.mbx.cepo-cms-support@health.mil
V/r,
DHA, J-7, CEPO
https://content.govdelivery.com/attachments/USMHS/2024/01/22/file_attachments/2757057/DHA_J-7_CEPO_22FEB24-CCSS-REGFlyer_vF_2024-01-19.pdf
lunes, 22 de enero de 2024
High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor Authors:Fangming Wang, Gang Zhang, Tianli Xu, Jianlin Ma, Jing Wang, Shuai Liu, Yuzhe Tang, Song Jin, Jianxing Li and Nianzeng Xing
Occupational Sitting Time, Leisure Physical Activity, and All-Cause and Cardiovascular Disease Mortality
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2814094?utm_term=011924&utm_campaign=ftm_links&utm_medium=referral&_hsmi=290867099&_hsenc=p2ANqtz--Z3xh0pYS6XpHBwVm9TxYEiT5duHp3Z18ecOiwFoXNIktPSsZwf78FaKvp6lr0II9jKoBo8SkMpVwzErRA89VTp70zzg&utm_source=For_The_Media
Despite your fancy standing desk, you’re still sitting too much
Jennifer Adaeze Okwerekwu
By Jennifer Adaeze Okwerekwu March 16, 2016
https://www.statnews.com/2016/03/16/sit-stand-desk/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=290867099&_hsenc=p2ANqtz--X7c9b0CeMPajuMIz2JQJzCGmxluzTYZ7lM0zfTuV0yYDu3_3c24YWc5ds1wzWywWDTQlz4YwW5cOAz5BBsHru7noVgA&utm_content=290867099&utm_source=hs_email
domingo, 21 de enero de 2024
Improving care for rare genetic neurodevelopmental disorders: a systematic review and critical appraisal of clinical practice guidelines using AGREE II. Mirthe J Klein Haneveld et al. Genet Med 2024 1 101071
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=archive&date=01/15/2024
From the abstract: "70 internationally published guidelines, addressing the diagnosis and/or management of 28 conditions, were included. The methodological rigor of development was highly variable with limited reporting of literature searches and consensus methods. Comprehensive, high-quality guidelines are lacking for many rare genetic neurodevelopmental disorders. Use and transparent reporting of sound development methodologies, active involvement of affected individuals and families, robust conflict of interest procedures, and attention to implementation are vital for enhancing the impact of clinical practice recommendations."
Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry. Kyung Min Lee et al. J Natl Cancer Inst 2024 1
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=all%20hot%20topics
From the abstract: "This cross-sectional retrospective analysis examines the association between a polygenic hazard score (PHS290) and risk of prostate cancer diagnosis upon first biopsy in male Veterans using two-sided tests. Our analysis included 36,717 Veterans (10,297 of African ancestry). Unadjusted rates of positive first prostate biopsy increased with higher genetic risk (low risk: 34%, high risk: 58%; p?
The American Academy of Microbiology discusses gain-of-function research of concern (GOFROC) and enhanced potential pandemic pathogens (ePPP). Arturo Casadevall et al. mBio 2023 12 (1) e0276123The American Academy of Microbiology discusses gain-of-function research of concern (GOFROC) and enhanced potential pandemic pathogens (ePPP). Arturo Casadevall et al. mBio 2023 12 (1) e0276123
Population Screening for Hereditary Hemochromatosis More than a Quarter Century After Gene Discovery – Current Status and the Path Forward February 15, 2024, 1:00 pm – 2:00 pm ET
https://www.cdc.gov/genomics/events/pop_screen_hereditary_hemochromatosis_2024.htm
Current data suggest that 1 in 300 non-Hispanic White individuals in the United States carry a genetic variation in the HFE gene (C282Y homozygosity) that accounts for most cases of hereditary hemochromatosis (HH). This variation can lead to iron overload and life-threatening complications, such as severe liver disease. However, complications are preventable with early diagnosis and periodic phlebotomies to remove excess iron from the body. At present, Tier 1 evidence-based guidelines support family-based genetic testing for HH. However, uncertainty remains concerning the best strategy for pre-symptomatic case identification and the suitability of HFE-associated HH as a target for population screening or ancestry-targeted screening using either measures of iron status or direct genetic testing. To devise optimal preventive strategies for HH, we must consider existing evidence about HH genetics, penetrance, and prevalence and the acceptability, cost, and effectiveness of potential screening strategies. In this webinar, our speakers will discuss how knowledge about HH has evolved since the discovery of the HFE gene in 1997, current opportunities for clinical and public health action to prevent disease, and future research priorities to advance case detection and reduce clinical complications from HH.
sábado, 20 de enero de 2024
FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma?utm_medium=email&utm_source=govdelivery
On January 19, 2024, the Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. This approval amends the indication previously granted under accelerated approval for patients with mUC with susceptible FGFR3 or FGFR2 alterations after prior platinum-containing chemotherapy.
viernes, 19 de enero de 2024
Basic Information About Cervical Cancer
Basic Information About Cervical Cancer
https://www.cdc.gov/cancer/cervical/basic_info/
Basic Information about HPV and Cancer
https://www.cdc.gov/cancer/hpv/basic_info/
What Should I Know About Screening?
https://www.cdc.gov/cancer/cervical/basic_info/screening.htm
HPV Vaccine
https://www.cdc.gov/hpv/parents/vaccine-for-hpv.html
Cervical & vaginal cancer screenings
https://www.medicare.gov/coverage/cervical-vaginal-cancer-screenings
Cindy’s Story: Preventing Cervical Cancer
https://www.cdc.gov/cancer/cervical/resources/index.htm
New Findings in Football Players May Aid the Future Diagnosis and Study of Chronic Traumatic Encephalopathy (CTE) Posted on January 18th, 2024 by Dr. Monica M. Bertagnolli
https://directorsblog.nih.gov/2024/01/18/new-findings-in-football-players-may-aid-the-future-diagnosis-and-study-of-chronic-traumatic-encephalopathy-cte/
Repeated hits to the head—whether from boxing, playing American football or experiencing other repetitive head injuries—can increase someone’s risk of developing a serious neurodegenerative condition called chronic traumatic encephalopathy (CTE). Unfortunately, CTE can only be diagnosed definitively after death during an autopsy of the brain, making it a challenging condition to study and treat. The condition is characterized by tau protein building up in the brain and causes a wide range of problems in thinking, understanding, impulse control, and more. Recent NIH-funded research shows that, alarmingly, even young, amateur players of contact and collision sports can have CTE, underscoring the urgency of finding ways to understand, diagnose, and treat CTE.
New findings published in the journal Neurology show that increased presence of certain brain lesions that are visible on MRI scans may be related to other brain changes in former football players. The study describes a new way to capture and analyze the long-term impacts of repeated head injuries, which could have implications for understanding signs of CTE.
The Division of Intramural Research Seminar Series
https://www.nei.nih.gov/events/intramural-research-seminars
Scanziani presents intramural seminar Feb. 1
Massimo Scanziani, University of California San Francisco, presents "Orienting eye movements in dreams and wakefulness," as part of the Division of Intramural Research Seminar Series, Thursday, Noon ET, NIH campus, Building 49, Room 1A51/1A52, and via Zoom.
Diabetes in America
https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america?utm_medium=e-mail&utm_source=News%20Releases%20%26%20Other%20News
Diabetes in America is the NIDDK’s compilation and assessment of epidemiologic, public health, clinical research, and clinical trial data focused on diabetes. This updated resource, developed by researchers at NIDDK and leading diabetes experts from around the country and world, is a one-stop source for crucial scientific information on diabetes, its complications and treatment, health care utilization, and diabetes prevention in the United States.
She’s hellbent on solving the organ shortage with ‘designer pigs.’ Just don’t keep her waiting Sharon Begley By Sharon Begley
https://www.statnews.com/2017/04/06/crispr-pig-organs-transplant-luhan-yang/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=290577490&_hsenc=p2ANqtz-88p43AuI1eKGqEOZFyq1XvWFhsQo200SBSn03L5us-U5OyuODkTqUdK-FSVJCAKmHMXU4JGYw2bCgNmUFO1pgzwl5Fqw&utm_content=290577490&utm_source=hs_email
When I hear about eGenesis, a pioneer in xenotransplantation deploying CRISPR to edit viruses out of pig organs, I think of its mission to solve the shortage of organs. That’s still its goal, but now the company is working with researchers at Penn Medicine to use human-friendly pig organs as a bridge for critically ill patients waiting to get better or to receive a human transplant. The technique is called extracorporeal perfusion and it circulates a patient’s blood through a genetically engineered pig organ kept alive in an incubator. Yesterday researchers said the procedure passed its first test in a brain-dead human.
STAT’s Megan Molteni describes it as “kind of like dialysis, except the guts of the machine are literal guts, from a pig.” Mike Curtis, eGenesis's CEO, told her “it’s not xenotransplant, but it’s a technology and a product that can fulfill a huge unmet need.” Caveat: Data from this experiment have not been published or made available as a preprint. Read more.
https://www.statnews.com/2024/01/18/egenesis-crispr-pig-liver-tested-in-brain-dead-patient/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=290577490&_hsenc=p2ANqtz-8JHU0UepejBlmeMYPBy9TzCRKn44trGmyRYIliNdWlKi5NUP-4GHIh-MwRpLsP1nUnDsB6vRYLvCGYlMi2CLsttB4j6A&utm_content=290577490&utm_source=hs_email
Hypothermia and frostbite: Easier to develop than you might think Tips to prevent and treat cold-related health problems
https://magazine.medlineplus.gov/article/hypothermia-and-frostbite-easier-to-develop-than-you-might-think?utm_medium=email&utm_source=govdelivery
What is hypothermia? Cold temperatures can cause hypothermia, which occurs when your body temperature drops below 95 degrees Fahrenheit (35 degrees Celsius). Hypothermia can lead to health problems like heart attacks, kidney problems, liver damage, or death. Warning signs include: Shivering Exhaustion Confusion Memory loss Fumbling hands Infants and older adults are especially at risk for hypothermia because they have a harder time regulating their body temperature. Medical conditions
Join Us at the International Congress on Integrative Medicine and Health in Cleveland January 18, 2024
I hope to see you at the in-person 2024 International Congress on Integrative Medicine and Health (ICIMH) in Cleveland, Ohio, from April 9 through April 13, 2024.
https://www.nccih.nih.gov/research/blog/join-us-at-the-international-congress-on-integrative-medicine-and-health-in-cleveland?nav=govd
I hope to see you at the in-person 2024 International Congress on Integrative Medicine and Health (ICIMH) in Cleveland, Ohio, from April 9 through April 13, 2024. As a member of the program committee for the Congress, I can tell you that we have a wonderful agenda planned, with an emphasis on one of the major challenges for our field—moving integrative health care strategies into mainstream care.
ICIMH, which is convened by the Academic Consortium for Integrative Medicine and Health, brings together leading figures from different fields to showcase recent scientific advancements in integrative medicine and health. It provides great opportunities for cross-disciplinary networking, along with an extensive schedule of presentations on original research, educational innovations, clinical delivery models, and policy challenges. Be sure to register by March 8, 2024, to avoid late fees.
Suscribirse a:
Entradas (Atom)
.png)
